Forte Biosciences and Pasithea Therapeutics Face Off in Financial Comparison

Analysts see more upside potential in Pasithea Therapeutics despite Forte Biosciences' stronger institutional backing.

Apr. 4, 2026 at 8:41am

Got story updates? Submit your updates here. ›

An extreme close-up of various metal and electronic components that make up the internal machinery of financial institutions, conveying the technical complexity and institutional power behind small-cap biotech companies.A detailed, cinematic view of the complex financial infrastructure powering the competitive biotech sector.Dallas Today

Pasithea Therapeutics (NASDAQ:KTTA) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but a new financial analysis suggests Pasithea Therapeutics may be the more favorable investment. While Forte Biosciences has stronger institutional ownership and insider holdings, Pasithea Therapeutics has a lower valuation and higher potential upside according to analysts.

Why it matters

This analysis provides valuable insights for investors looking to compare the financial prospects of these two emerging biotech firms. The findings highlight key differences in factors like volatility, valuation, and profitability that could sway investment decisions in the competitive small-cap medical space.

The details

The analysis found that Forte Biosciences has significantly higher institutional ownership at 77.6% compared to just 23.9% for Pasithea Therapeutics. Forte Biosciences also has a higher percentage of insider ownership at 5.9% versus 2.0% for Pasithea. However, Pasithea Therapeutics has a much lower beta of 0.25, indicating its share price is 75% less volatile than the S&P 500, while Forte Biosciences has a high beta of 3.2. Analysts also see more potential upside in Pasithea Therapeutics, with a consensus price target of $3.00 suggesting a 289.66% increase, compared to 161.92% for Forte Biosciences.

  • The analysis was published on April 4, 2026.

The players

Pasithea Therapeutics

A biotechnology company engaged in the discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase (MEK) inhibitor.

Forte Biosciences

A biopharmaceutical company developing treatments for autoimmune diseases, including graft-versus-host disease, vitiligo, and alopecia areata. Its lead program is FB-102.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the complex factors investors must weigh when comparing small-cap biotech firms like Pasithea Therapeutics and Forte Biosciences. While Forte Biosciences has stronger institutional backing, Pasithea Therapeutics may offer more potential upside based on its lower valuation and higher analyst price targets. Investors will need to closely monitor the progress of each company's drug development pipelines to determine which is the better long-term investment.